title: Inhibition of neuronal degenerin/epithelial Na+ channels by the multiple sclerosis drug 4-aminopyridine.
abstract: The voltage-gated K(+) (Kv) channel blocker 4-aminopyridine (4-AP) is used to target symptoms of the neuroinflammatory disease multiple sclerosis (MS). By blocking Kv channels, 4-AP facilitates action potential conduction and neurotransmitter release in presynaptic neurons, lessening the effects of demyelination. Because they conduct inward Na(+) and Ca(2+) currents that contribute to axonal degeneration in response to inflammatory conditions, acid-sensing ion channels (ASICs) contribute to the pathology of MS. Consequently, ASICs are emerging as disease-modifying targets in MS. Surprisingly, as first demonstrated here, 4-AP inhibits neuronal degenerin/epithelial Na(+) (Deg/ENaC) channels, including ASIC and BLINaC. This effect is specific for 4-AP compared with its heterocyclic base, pyridine, and the related derivative, 4-methylpyridine; and akin to the actions of 4-AP on the structurally unrelated Kv channels, dose- and voltage-dependent. 4-AP has differential actions on distinct ASICs, strongly inhibiting ASIC1a channels expressed in central neurons but being without effect on ASIC3, which is enriched in peripheral sensory neurons. The voltage dependence of the 4-AP block and the single binding site for this inhibitor are consistent with 4-AP binding in the pore of Deg/ENaC channels as it does Kv channels, suggesting a similar mechanism of inhibition in these two classes of channels. These findings argue that effects on both Kv and Deg/ENaC channels should be considered when evaluating the actions of 4-AP. Importantly, the current results are consistent with 4-AP influencing the symptoms of MS as well as the course of the disease because of inhibitory actions on Kv and ASIC channels, respectively.
authors: Department of Physiology, University of Texas Health Sciences Center, San Antonio, TX 78229, USA.
authors: Nina
authors: N
authors: Boiko
authors: Volodymyr
authors: V
authors: Kucher
authors: Benjamin A
authors: BA
authors: Eaton
authors: James D
authors: JD
authors: Stockand
mesh_terms: D015761:4-Aminopyridine / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn; D016466:CHO Cells; D006224:Cricetinae; D062626:Degenerin Sodium Channels / Q000378:metabolism*; D004331:Drosophila melanogaster; D053503:Epithelial Sodium Channels / Q000378:metabolism*; D006624:Hippocampus / Q000378:metabolism; D020128:Inhibitory Concentration 50; D051379:Mice; D008810:Mice, Inbred C57BL; D009103:Multiple Sclerosis / Q000378:metabolism*; D019636:Neurodegenerative Diseases / Q000378:metabolism; D009474:Neurons / Q000378:metabolism*; D018408:Patch-Clamp Techniques; D026902:Potassium Channel Blockers / Q000494:pharmacology; D015221:Potassium Channels / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D062626:Degenerin Sodium Channels; D053503:Epithelial Sodium Channels; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D015761:4-Aminopyridine
references: Peptides. 2006 May;27(5):1138-52
references: 16516345
references: Acta Pharmacol Sin. 2013 Jan;34(1):33-8
references: 22820909
references: J Physiol. 2001 Aug 15;535(Pt 1):145-53
references: 11507165
references: Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16556-61
references: 17060608
references: J Biol Chem. 2009 Dec 25;284(52):36453-36461
references: 19850918
references: Ann N Y Acad Sci. 1999 Apr 30;868:67-76
references: 10414282
references: Dev Neurobiol. 2007 Jan;67(1):97-107
references: 17443775
references: Clin Neuropharmacol. 1993 Jun;16(3):195-204
references: 8504436
references: Nature. 2009 Jul 30;460(7255):599-604
references: 19641589
references: J Gen Physiol. 1993 Nov;102(5):797-816
references: 8301258
references: Chem Biodivers. 2012 Feb;9(2):331-51
references: 22344909
references: Brain. 2011 Feb;134(Pt 2):571-84
references: 21233144
references: Am J Physiol Cell Physiol. 2012 Oct 1;303(7):C699-710
references: 22843794
references: J Biol Chem. 2002 Nov 29;277(48):45734-40
references: 12244121
references: Biophys J. 2001 Aug;81(2):895-904
references: 11463633
references: Nature. 1997 Mar 13;386(6621):173-7
references: 9062189
references: Brain. 2000 Feb;123 ( Pt 2):308-17
references: 10648438
references: Mol Pharmacol. 2011 Nov;80(5):911-9
references: 21828194
references: Science. 2005 Aug 5;309(5736):897-903
references: 16002581
references: Neuroscience. 2002;110(4):723-30
references: 11934479
references: Nature. 2007 Sep 20;449(7160):316-23
references: 17882215
references: Neurology. 2007 May 29;68(22 Suppl 3):S22-31; discussion S43-54
references: 17548565
references: Biophys J. 1988 Oct;54(4):757-64
references: 2465033
references: J Neurol Sci. 2007 Aug 15;259(1-2):3-6
references: 17367814
references: FASEB J. 2012 Oct;26(10):4122-30
references: 22735174
references: Bioorg Med Chem Lett. 2012 Jan 15;22(2):929-32
references: 22197144
references: J Biol Chem. 2012 Nov 16;287(47):39878-86
references: 23033486
references: J Gen Physiol. 1993 Apr;101(4):603-26
references: 8505628
references: Nat Med. 2007 Dec;13(12):1483-9
references: 17994101
references: J Biol Chem. 2004 Mar 19;279(12):11006-15
references: 14701823
references: Muscle Nerve. 2007 Apr;35(4):451-7
references: 17206661
references: Cell. 2004 Sep 17;118(6):687-98
references: 15369669
references: Ann Pharmacother. 2008 Oct;42(10):1458-65
references: 18780812
references: J Neurosci. 2005 Oct 26;25(43):9960-7
references: 16251444
references: Chem Rev. 2008 May;108(5):1744-73
references: 18476673
references: J Gen Physiol. 1984 Aug;84(2):157-86
references: 6092514
references: J Physiol. 1999 Sep 1;519 Pt 2:323-33
references: 10457052
references: FEBS Lett. 2000 Apr 14;471(2-3):205-10
references: 10767424
references: J Gen Physiol. 1982 Jul;80(1):1-18
references: 6288835
references: Pharmacol Ther. 2006 Jul;111(1):224-59
references: 16472864
references: Mol Pharmacol. 2011 Dec;80(6):1085-95
references: 21926190
references: Trends Neurosci. 2003 Sep;26(9):477-83
references: 12948658
references: Am J Pathol. 2000 Jul;157(1):267-76
references: 10880396
references: J Vis Exp. 2007;(5):226
references: 18979024
references: Nat Rev Neurosci. 2006 Dec;7(12):932-41
references: 17115075
references: Physiol Rev. 2002 Jul;82(3):735-67
references: 12087134
references: Ann Neurol. 2006 Mar;59(3):478-89
references: 16392116
references: J Gen Physiol. 1992 Feb;99(2):217-40
references: 1613484
references: J Neurol Sci. 2005 Jun 15;233(1-2):3-13
references: 15899499
references: J Biol Chem. 1997 Nov 21;272(47):29778-83
references: 9368048
references: J Exp Med. 1958 Dec 1;108(6):945-56
references: 13598821
references: Cochrane Database Syst Rev. 2002;(4):CD001330
references: 12804404
references: Biophys J. 2011 Apr 20;100(8):1930-9
references: 21504729